OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EARK56

earKART Ltd

Advanced Medical Equipment & TechnologyVerified

Capital Structure and Liquidity earKART maintains a debt-to-equity ratio of 0.25, indicating a conservative capital structure with limited leverage. The company's liquidity position is characterized as medium, with a current ratio of 2.65, suggesting it can cover short-term obligations but with limited excess cash. Free cash flow of INR 136.59 million reflects strong cash generation, though cash and equivalents are relatively low at INR 3.66 million. ### Profitability and Returns The company's return on equity (ROE) of 69.11% and return on assets (ROA) of 45.43% are significantly above industry norms, indicating strong profitability and efficient use of capital. Gross profit of INR 174.90 million and operating income of INR 186.77 million support this performance, with net income of INR 137.63 million translating to a net margin of 31.93%. ### Segments and Geographic Exposure The company operates in a single disclosed segment focused on hearing aids and related products. Revenue is concentrated in India, with no material international operations disclosed. The company's product portfolio includes a range of hearing aid types and assistive devices for the physically challenged. ### Growth Trajectory While specific growth projections are not provided, the company's strong free cash flow and high ROE suggest a solid foundation for reinvestment or shareholder returns. The development of the OMNI remote audiometry machine represents a potential growth driver by expanding access to hearing aid services. ### Risk Factors The company faces a medium liquidity risk due to a current ratio of 2.65 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution events or share issuance plans disclosed in the latest financials. ### Recent Events No recent filings or transcripts are provided in the input data to inform recent corporate developments or strategic shifts.

30-day price · EARK+27.75 (+22.9%)
Low$120.00High$160.00Close$148.75As of17 May, 00:00 UTC
Profile
CompanyearKART Ltd
TickerEARK.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. earKART Limited is an India-based company engaged in the manufacturing and distribution of hearing aids and related accessories, including products for the physically challenged and a Remote Audiometry Machine (OMNI).

Classification. The company is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

### Capital Structure and Liquidity earKART maintains a debt-to-equity ratio of 0.25, indicating a conservative capital structure with limited leverage. The company's liquidity position is characterized as medium, with a current ratio of 2.65, suggesting it can cover short-term obligations but with limited excess cash. Free cash flow of INR 136.59 million reflects strong cash generation, though cash and equivalents are relatively low at INR 3.66 million. ### Profitability and Returns The company's return on equity (ROE) of 69.11% and return on assets (ROA) of 45.43% are significantly above industry norms, indicating strong profitability and efficient use of capital. Gross profit of INR 174.90 million and operating income of INR 186.77 million support this performance, with net income of INR 137.63 million translating to a net margin of 31.93%. ### Segments and Geographic Exposure The company operates in a single disclosed segment focused on hearing aids and related products. Revenue is concentrated in India, with no material international operations disclosed. The company's product portfolio includes a range of hearing aid types and assistive devices for the physically challenged. ### Growth Trajectory While specific growth projections are not provided, the company's strong free cash flow and high ROE suggest a solid foundation for reinvestment or shareholder returns. The development of the OMNI remote audiometry machine represents a potential growth driver by expanding access to hearing aid services. ### Risk Factors The company faces a medium liquidity risk due to a current ratio of 2.65 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution events or share issuance plans disclosed in the latest financials. ### Recent Events No recent filings or transcripts are provided in the input data to inform recent corporate developments or strategic shifts.
Key takeaways
  • earKART demonstrates strong profitability with ROE of 69.11% and ROA of 45.43%.
  • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.25.
  • Free cash flow of INR 136.59 million supports reinvestment or shareholder returns.
  • Revenue is concentrated in India, with no material international operations disclosed.
  • The OMNI remote audiometry machine represents a potential growth driver.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$431.1M
Gross profit$174.9M
Operating income$186.8M
Net income$137.6M
R&D
SG&A
D&A
SBC
Operating cash flow$14.2M
CapEx-$5.3M
Free cash flow$136.6M
Total assets$302.9M
Total liabilities$103.8M
Total equity$199.2M
Cash & equivalents$3.7M
Long-term debt$49.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$199.2M
Net cash-$45.9M
Current ratio2.6
Debt/Equity0.2
ROA45.4%
ROE69.1%
Cash conversion10.0%
CapEx/Revenue-1.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
MetricEARKActivity
Op margin43.3%19.4% medp25 17.8% · p75 22.0%top quartile
Net margin31.9%17.7% medp25 16.4% · p75 19.0%top quartile
Gross margin40.6%73.5% medp25 71.3% · p75 75.8%bottom quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-1.2%4.3% medp25 3.9% · p75 4.3%bottom quartile
Debt / equity25.0%41.5% medp25 29.2% · p75 51.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 08:08 UTC#66618555
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 08:10 UTCJob: 32057e38